PHARMATHENE kurslich bald ne Hot-Stock
Seite 1 von 6
neuester Beitrag: 13.07.18 20:36
|eröffnet am:||06.10.12 09:52 von:||buran||Anzahl Beiträge:||143|
|neuester Beitrag:||13.07.18 20:36 von:||Balu4u||Leser gesamt:||16981|
|bewertet mit 1 Stern
buran : PHARMATHENE kurslich bald ne Hot-Stock
SparVax? - a second generation recombinant protective antigen (rPA) anthrax vaccine
Recombinant BChE- a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents
Valortim® - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
In addition, pursuant to a final judgment issued May 31, 2012 from the Delaware Court of Chancery, PharmAthene is entitled to 50% of the net profits over 10 years from all sales of SIGA Technologies' ST-246®, a novel smallpox antiviral agent being developed by SIGA for the treatment and prevention of morbidity and mortality associated with exposure to the causative agent of smallpox, and related products, once SIGA receives the first $40 million in net profits from sales of ST-246®. For more information about PharmAthene, please visit www.PharmAthene.com.
Cobra7 : @money
The proposed transaction does not affect PharmAthene's previously announced special one-time cash dividend of $2.91 per share of common stock.